Soteria Biotherapeutics, Inc.
Antibody-based chemically induced dimerizier (AbCID) molecular switches for controlling T cell therapy activity via small-molecule drugs
Follows are private to you and power your alerts
Updated · soteriabiotherapeutics.com
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Founded
- 2018
- Latest Form D
- $24.9M, May 2021
- Total capital
- $25.2M
- Federal grants
- $300K
- 1 award · 2019
- Rank in peer group#63 of 392
- Private capital raised
- $24.9M
- 1 Form D · last May 2021
- 65 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$24.9M
- Federal grantHealth and Human S · Phase I · Development of a chemically regulated immunotherapy for B-cell malignancies$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
26months
from Soteria Biotherapeutics, Inc.’s first federal award to its first private round.
- First federal award · Apr 2019
- Health and Human S · $300K
- First Form D · May 2021
- $24.9M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#63 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David M AllisonDirectorNamed in SEC Form D filings
- David M MorrisDirectorNamed in SEC Form D filings
- Keno M GutierrezDirectorNamed in SEC Form D filings
- Kristine M BallExecutive Officer, DirectorNamed in SEC Form D filings
- Momo M WuDirectorNamed in SEC Form D filings
- Nisha M MaratheDirectorNamed in SEC Form D filings
Show all 8 people
- Steve M JamesDirectorNamed in SEC Form D filings
- Zachary M HillExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 9- PendingChemically Induced Association and Dissociation of Therapeutic FC Compositions and Chemically Induced Dimerization of T Cell Engager with Human Serum AlbuminUSPTOApplication 17788418
- PendingSingle And Dual Targeting Ligand Induced T-cell Engager CompositionsUSPTOApplication PCTUS2021044099
- PendingIndinavir Based Chemical Dimerization T Cell Engager CompositionsUSPTOApplication 63136111
Show all 9 patent records
- Chemically Induced Association and Dissociation of Therapeutic FC Compositions and Chemically Induced Dimerization of T Cell Engager with Human Serum AlbuminFeb 16, 2023 · Application 17788418Pending
- Single And Dual Targeting Ligand Induced T-cell Engager CompositionsApplication PCTUS2021044099Pending
- Indinavir Based Chemical Dimerization T Cell Engager CompositionsApplication 63136111Pending
- Chemically Induced Association And Dissociation Of Therapeutic Fc Compositions And Chemically Induced Dimerization Of T Cell Engager With Human Serum AlbuminApplication PCTUS2020066865Pending
- Single Targeting Ligand Induced Enhanced T-cell Engager CompositionsApplication 63083827Pending
- Dual Targeting Ligand Induced T-cell Engager CompositionsApplication 63083828Pending
- Single Targeting Ligand Induced T-cell Engager CompositionsApplication 63059516Pending
- Chemically Induced Dimerization Of T Cell Engager With Human Serum Albumin And The Uses ThereofApplication 62953003Pending
- Chemically Induced Association And Dissociation Of Therapeutic Fc CompositionsApplication 62952984Pending
Related companies, and why
- SimBioSys, Inc.Similar federal contract value in Biotech · null in contracts
- C4 TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ASTROCYTE PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- NATURA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- AMIDEBIO, LLCSimilar federal contract value in Biotech · null in contracts
- Calder Biosciences Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .